New Dermal Filler for Chin Correction and Augmentation

A Randomized, Evaluator-blinded, Parallel Group, no Treatment Controlled, Multi-center Study to Evaluate Effectiveness and Safety of GP0109 for Augmentation and Correction of Retrusion in the Chin Region

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04631263

Enrollment

140

Registered

2020-11-17

Start date

2021-01-29

Completion date

2022-06-16

Last updated

2022-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chin Augmentation and Correction

Brief summary

Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GP0109 for augmentation and correction or retrusion in the chin region in Canada

Interventions

DEVICEHyaluronic Acid

Injectable gel. Chin correction and augmentation for retrusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* subject willing to comply with the requirements of the study * subject intent to receive treatment for augmentation and correction of retrusion in the chin region * subject with mild or moderate (grade 1 or 2) on the GCRS

Exclusion criteria

* subjects presenting with know allergy to HA (hyaluronic acid) filler or amide local anesthetics * subjects with any previous facial surgery below the nasal line or previous HA filler or collagen below the nasal line within 12 months * subjects in any other interventional clinical study within 30 days before baseline

Design outcomes

Primary

Measure	Time frame
Responder rate based on the Galderma Chin Retrusion Scale as assessed live by the Blinded Evaluator	3 months after baseline

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026